Tetra: Fiscal Q3 Earnings Snapshot
The Pasadena, California-based company said it had profit of 43 cents per share.
The consulting and engineering services company posted revenue of $1.37 billion in the period. Its adjusted revenue was $1.15 billion.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Enbridge Beats Q2 Adjusted Earnings Estimates, Expects to Hit Financial Guidance for 20th Straight Year
Enbridge ( reported Friday adjusted earnings in the second quarter that beat analysts' expect Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Regeneron shares edge higher as second quarter earnings surpass estimates
-- Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst expectations, with adjusted earnings per share reaching $12.89 compared to the $8.43 consensus estimate. Revenue also beat forecasts, coming in at $3.68 billion versus the expected $3.28 billion. The biopharmaceutical company's total revenue increased 4% YoY, driven by strong performance across several key products. Dupixent global net sales, recorded by Sanofi (NASDAQ:SNY), grew 22% to $4.34 billion, while EYLEA HD U.S. net sales jumped 29% to $393 million. However, combined EYLEA HD and EYLEA U.S. net sales decreased 25% to $1.15 billion. The stock is up 0.3% following the results. "Regeneron (NASDAQ:REGN) had a strong quarter, marked by significant growth in U.S. sales of EYLEA HD and global sales of Dupixent and Libtayo along with multiple regulatory approvals," said Leonard Schleifer, Chief Executive Officer of Regeneron. The company reported several regulatory achievements during the quarter, including FDA approval for Lynozyfic for relapsed or refractory multiple myeloma and Dupixent approvals for bullous pemphigoid and chronic spontaneous urticaria. The FDA also accepted for priority review Libtayo's application for adjuvant cutaneous squamous cell carcinoma. Regeneron updated its financial guidance for 2025, adjusting its R&D and SG&A expense projections. The company now expects non-GAAP R&D expenses of $5.1-$5.2 billion and non-GAAP SG&A expenses of $2.45-$2.55 billion. During the quarter, Regeneron returned over $2.3 billion to shareholders through share repurchases and dividends. The company's board declared a cash dividend of $0.88 per share, payable on September 3, 2025. Related articles Regeneron shares edge higher as second quarter earnings surpass estimates These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia Apollo economist warns: AI bubble now bigger than 1990s tech mania Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
CDW Names Mukesh Kumar Chief Services and Solutions Officer
VERNON HILLS, Ill., August 01, 2025--(BUSINESS WIRE)--CDW (Nasdaq: CDW) announced today that Mukesh Kumar will join the company as Chief Services and Solutions Officer on August 4, 2025, reporting to Chair and Chief Executive Officer, Christine A. Leahy. Kumar will lead CDW's services and solutions business, comprised of our Integrated Technology Solutions and Digital Velocity practices. Kumar joins CDW from Slalom Consulting, where he most recently served as president of the multibillion-dollar technology business. Kumar brings to CDW deep technical depth across a broad spectrum of emerging technologies and long-standing experience driving transformative change. At Slalom, Kumar scaled their technology-based services teams across the Americas and led Slalom's technology partner ecosystem of 800+ partnerships, including AWS, Salesforce, Microsoft, and Google. Kumar brings nearly 30 years of technology and consulting leadership and is highly regarded in the technology community for his creative and forward-thinking solutioning and ability to incubate, grow, and scale businesses. "At CDW, our purpose is simple: to make technology work so people can do great things," said Christine A. Leahy, Chair and Chief Executive Officer, CDW. "Our customers trust us as a strategic partner to help them navigate the dynamic and increasingly complex technology ecosystem and achieve their business and mission goals. Our technology services and solutions capabilities are crucial to meeting them where they are in their full-stack and lifecycle journey. Mukesh's experience developing and scaling technology-based services and solutions will be invaluable as CDW continues to aggressively invest in these capabilities." About CDW CDW Corporation (Nasdaq: CDW) is a leading multi-brand provider of information technology solutions to business, government, education and healthcare customers in the United States, the United Kingdom and Canada. A Fortune 500 company and member of the S&P 500 Index, CDW helps its customers to navigate an increasingly complex IT market and maximize return on their technology investments. For more information about CDW, please visit View source version on Contacts Investor Inquiries Steve O'BrienSenior Vice President, Investor Relations(847) 968-0238investorrelations@ Media Inquiries Sara GranackVice President, Corporate Communications(847) 419-7411mediarelations@ 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
